Locations:
September 9, 2024/Innovations

Fierce Names Cleveland Clinic Innovations as One of its 50 Honorees of 2024

This year’s Fierce 50 Innovation honorees are visionaries, risk-takers and disruptors who refuse to accept the status quo and are united by their pursuit of progress. Cleveland Clinic Innovations is honored to be recognized for turning big ideas into tangible results that transform patient care.

Fierce 50 Honoree Badge Logo

Fierce Life Sciences and Fierce Healthcare have named Cleveland Clinic Innovations as one of 2024’s Fierce 50 honorees. The Fierce 50 showcases 50 individuals and companies driving advancements in medicine, fostering innovation and shaping the future of biopharma and healthcare.

“The annual Fierce 50 special report highlights individuals and companies that are driving progress in the pharmaceutical, healthcare and biotechnology industries,” said Ayla Ellison, Editor-in-Chief of Fierce Life Sciences and Healthcare. “These 50 outstanding organizations and people demonstrate excellence in their fields, and their commitment to innovation, equity and improving lives is truly commendable. Congratulations to this year’s honorees.”

Cleveland Clinic Innovations, founded in 2000, has significantly impacted the advancements in the medical field by earning over 2,500 patents, 840 licenses, and spinning out 105 startups. The organization employs a unique "team of teams" approach to innovation, which includes groups dedicated to engagement, assessment, product development, licensing, and creating new companies. This method enables Innovations to innovate effectively with a focus on patient-centered outcomes, including transformative developments in pediatric health, remote patient monitors, neurostimulation devices, and cancer vaccine candidates.

Looking forward, Cleveland Clinic Innovations is expanding its focus beyond medical devices into areas like artificial intelligence, digital health, pharmaceuticals, and diagnostics. The organization is also exploring "outside-in" innovation by collaborating with external companies to bring transformative technologies to the Cleveland Clinic health system. These initiatives, along with expanding their global reach, reflect their commitment to enhancing operational efficiency and improving patient care across all conditions.

“One of the overriding values that we look at is, what effect is this going to have on the patients? Is this something that is really going to transform clinical care?” said Geoff Vince, PhD, Executive Director, Cleveland Clinic Innovations. “If it is, we will obviously prioritize that above everything else that we work on. For us, making it patient-centered is our North Star.”

The Fierce 50 is a constellation of the most brilliant visionaries and trailblazers, handpicked by the discerning editors of Fierce Biotech, Fierce Pharma and Fierce Healthcare. These individuals and companies are a driving force in healthcare delivery, drug development, research, and more.

Read the full Cleveland Clinic Innovations Fierce 50 honoree feature at Fierce Pharma.

Subscribe to Cleveland Clinic Innovations' Newsletter

Follow Cleveland Clinic Innovations on LinkedIn

Latest from the Newsroom

Photo of scale wit a tape measure.

Cleveland Clinic Study Identifies Best Treatment Strategies for Weight Loss After Stopping GLP-1 Drugs

Cleveland Clinic's new teaching kitchen and food pantry at the Langston Hughes Community Health & Education Center

Cleveland Clinic Opens Teaching Kitchen and Food Pantry on Cleveland's East Side

VeloSano riders

$20.2 Million Raised for VeloSano, Funding Cancer Research at Cleveland Clinic in 2026

Photo of spine imaging.

Cleveland Clinic Expands Orthopaedic Care in the Mahoning Valley Through Acquisition of Youngstown Orthopaedic Associates Practice

Lobby of new Toronto location

Cleveland Clinic Canada Moves to New Downtown Toronto Location

Artist's rendering of gene therapy for high triglycerides.

Gene Editing Therapy Trial Dramatically Lowers Dangerous Blood Fat Levels

Artist's illustration of gene editing

Cleveland Clinic First-in-Human Trial Shows Gene-Silencing Therapy for High Cholesterol to Be Safe and Effective

Medical illustration of lipoprotein(a) molecule

Cleveland Clinic Trial Shows Novel Lipoprotein(a) Drug Did Not Reduce Major Cardiovascular Events After Nearly 5 Years